Size-Exclusion Ultra Performance Liquid Chromatography Analysis of Insulin


The Application Notebook

The Application NotebookThe Application Notebook-07-02-2012
Volume 0
Issue 0

Waters Application Note

Insulin was the first recombinant pharmaceutical produced. Currently, one of the critical quality control attributes of therapeutic insulin in the US and European Pharmacopoeia (USP and EP) monograph is the level of covalent high molecular weight (HMW) insulin as determined by HPLC size-exclusion chromatography. Presented in this application are the advantages that may be realized using a125 Å pore size, sub2-µm ethylene-bridged hybrid (BEH) silica packing material and Waters Ultra Performance liquid chromatography (UPLC®) instrumentation for the pharmacopoeial analysis of covalent HMW impurities in therapeutic insulin samples. Among these advantages are faster run times, higher sensitivity and higher resolving separations of insulin and covalent insulin HMW, while at the same time greatly reducing acetonitrile containing waste-stream volumes.

Instrumentation and Consumables

LC Conditions

Instrument: ACQUITY® UPLC H-Class Bio System with TUV detector and titanium flow cell

Columns: ACQUITY UPLC® BEH125 SEC, 1.7 µm, 4.6 × 300 mm (part number 186006506) and Insulin HMWP HPLC, 10 µm, 7.8 × 300 mm (part number WAT201549)

Mobile phase: L-arginine (1.0 g/L)/acetic acid (99%)/acetonitrile; 65/15/20 (v/v/v)

Column temp.: 25 °C

Sample temp.: 10 °C

Flow-rate: 0.4 mL/min for the ACQUITY® UPLC BEH125 SEC column and 0.5 mL/min for the HMWP HPLC column

Detection: UV @ 276 nm

Injection volume: 10 µL for ACQUITY® UPLC BEH125 SEC column and 100 µL for the Insulin HMWP HPLC column

Results and Discussion

For this application a comparison was performed between two SEC columns with particle sizes of 1.7 µm (UPLC) and 10 µm (HPLC) that are of comparable 125 Å pore size and equivalent 30 cm length (Figure 1). While both columns met the EP and USP HMW peak-to-valley ratio (P/V) system suitability criterion of NLT 2, and produced comparable HMW peak quantitation, the average HMW P/V for the UPLC® column (P/V = 37) was more than four times higher than that of the HPLC column (P/V = 8) and an insulin fragment was partially resolved at the tail of the monomer peak. In addition to dramatically increased resolution, the UPLC column also provides a smaller total elution volume (~ 5 mL) than the HPLC column. This decrease in total elution volume provides the analyst with increased sample throughput in addition to a decrease in mobile-phase use.

Figure 1: Zoomed view of chromatograms of a biotherapeutic insulin sample (analysed past expiry) generated by the ACQUITY UPLC BEH125 and the Waters HMWP columns. The complete chromatographic profiles are presented in the insets.


The use of 125 Å pore size, sub-2-µm ethylene-bridged hybrid (BEH) silica packing material and Waters Ultra Performance liquid chromatography (UPLC) instrumentation for this traditional SEC-based analysis provides significant improvements in resolution compared to traditional SE-HPLC methods while reducing analysis time and mobile-phase use.

©2012 Waters Corporation. Waters, ACQUITY UPLC, UPLC, Alliance are trademarks of Waters Corporation.

Related Videos
Related Content